Key facts
- EndoSound’s last known valuation is $24.5M (Aug 2025).
- It has raised $8.5M across 4 recorded rounds; the latest was Seed Round ($250K) in Jun 2026.
- Notable investors include GEO MedTech Ventures, American Gastroenterological Association, Oregon Bioscience Incubator, Varia Ventures.
- EndoSound has filed 5 Form Ds with the SEC since 2021, most recently Aug 2025 ($1.9M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for EndoSound
Funding rounds
4 roundsAbout EndoSound
Developer of an ultrasound imaging system designed to cater to gastrointestinal patient care with a fully functional endoscopic ultrasound (EUS) scope. The company's system offers an adaptive design that allows providers to easily convert existing flexible video gastroscopes from the major endoscope manufacturers into ultrasound endoscopes at a fraction of the cost integrates into hospitals and ASCs of any size or location, and serves as a tool in the diagnosis and treatment of a wide variety of benign and malignant disorders of the digestive tract, most prominently those of the pancreas, enabling patients and physicians to get access to EUS while reducing overall health care costs.
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2016
- Employees
- 14
- Website
- endosound.com/
- Ownership
- Privately Held (backing)
EndoSound doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoSound shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoSound in its N-PORT filings yet. We sweep new filings monthly.